Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
NCT ID: NCT02604498
Last Updated: 2018-03-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-04-14
Study Completion Date
2018-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to moderate hepatic function impaired (Child-Pugh B，7-9) subjects in age, gender and weight as parallel control, which matches healthy with normal hepatic function according to the of subjects with impaired hepatic function as, after enrollment of subjects with moderate impaired hepatic function (Child-Pugh B，7-9). Hepatic function impaired group and control group both receive orally single-dose of nemonoxacin malate capsule (0.5g). Collect the blood and urine samples before and after the administration to perform pharmacokinetic analysis and safety observation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
NCT01012284
Moderate Hepatic Impairment
COMPLETED
PHASE1
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
NCT05116826
Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases
COMPLETED
PHASE1
Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
NCT03306667
Hepatic Insufficiency
Healthy
COMPLETED
PHASE1
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
NCT06985615
Hepatic Impairment
Healthy Volunteers
RECRUITING
PHASE1
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
NCT05386589
Hepatic Impairment
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Single dose study: evaluate safety and tolerability of oral nemonoxacin capsule 500mg.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Liver Dysfunction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver function impaired
Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
Group Type
EXPERIMENTAL
Nemonoxacin
Intervention Type
DRUG
Single dose 500mg oral
Healthy Subjects
Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
Group Type
EXPERIMENTAL
Nemonoxacin
Intervention Type
DRUG
Single dose 500mg oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nemonoxacin
Single dose 500mg oral
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Nemonoxacin Malate Capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with hepatic impairment
1. male or female aged 18 to 70 years；
2. has a body mass index of 17 to 30 kg/m2；
3. eGRF\>50ml/min/1.73m2；
4. Patients in stable condition with moderate impaired hepatic function, due to viral hepatitis, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis or other causes, and determined to be level B according to Child-Pugh classification；
5. B-ultrasonography, CT or MRI shows or biopsy confirm that have a positive diagnosis of cirrhosis ；
6. Has stable regimen of treatment of hepatic function impaired for 3 months prior to enrollment;
7. Female volunteers must meet:
1. Has sterilization operation, or who are postmenopausal must have been postmenopausal for \>1 year, or
2. Has childbearing potential, but meet the requirement as following:
Negative pregnancy test prior to enrollment, and Agree with use 1 medical accepted methods of birth control (eg. Hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) during the whole study and continuing until 1 month after the end of the study, and Non-breastfeeding;
8. Male volunteers must agree to use medical accepted method of birth control (e.g. barrier contraceptive or sexual partner use the method as (7) above) during the study and through 1month after the end of study；
9. Agree stay in ward prior to dosing within 48h, and agree not to take coffee, tea, chocolate, alcohol, grapefruit juice, orange juice and other food and drink which contain caffeine and xanthine；
10. Can sign informed consent form on his own accord；
11. Can comply with study procedures
Healthy subjects without hepatic impairment
1. Male or female volunteers (matched to a subject with hepatic impairment in gender）；
2. Aged 18 to 70 years (matched to a subject with hepatic impairment±5 years, matched range cannot exceed±5 years)；
3. Has a body mass index of 17 to 30 kg/m2（matched to a subject with hepatic impairment±15%，matched range cannot exceed±15%）；
4. Must be in good health as determined by screening medical history, physical examination, vital signs, laboratory test, B ultrasonography and chest X ray；
5. Female volunteers must meet:
1. Has sterilization operation, or who are postmenopausal must have been postmenopausal for \>1 year, or
2. Has childbearing potential, but meet the requirement as following:
Negative pregnancy test prior to enrollment, and Agree with use 1 medical accepted methods of birth control (eg. Hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) during the whole study and continuing until 1month after the end of the study, and Non-breastfeeding；
6. Male volunteers must agree to use medical accepted method of birth control (e.g. barrier contraceptive or sexual partner use the method as (7) above) during the study and through 1month after the end of study；
7. Agree stay in ward prior to dosing within 48h, and agree not to take coffee, tea, chocolate, alcohol, grapefruit juice, orange juice and other food and drink which contain caffeine and xanthine；
8. Can sign informed consent form on his own accord；
9. Can comply with study procedures
1. male or female aged 18 to 70 years；
2. has a body mass index of 17 to 30 kg/m2；
3. eGRF\>50ml/min/1.73m2；
4. Patients in stable condition with moderate impaired hepatic function, due to viral hepatitis, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis or other causes, and determined to be level B according to Child-Pugh classification；
5. B-ultrasonography, CT or MRI shows or biopsy confirm that have a positive diagnosis of cirrhosis ；
6. Has stable regimen of treatment of hepatic function impaired for 3 months prior to enrollment;
7. Female volunteers must meet:
1. Has sterilization operation, or who are postmenopausal must have been postmenopausal for \>1 year, or
2. Has childbearing potential, but meet the requirement as following:
Negative pregnancy test prior to enrollment, and Agree with use 1 medical accepted methods of birth control (eg. Hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) during the whole study and continuing until 1 month after the end of the study, and Non-breastfeeding;
8. Male volunteers must agree to use medical accepted method of birth control (e.g. barrier contraceptive or sexual partner use the method as (7) above) during the study and through 1month after the end of study；
9. Agree stay in ward prior to dosing within 48h, and agree not to take coffee, tea, chocolate, alcohol, grapefruit juice, orange juice and other food and drink which contain caffeine and xanthine；
10. Can sign informed consent form on his own accord；
11. Can comply with study procedures
Healthy subjects without hepatic impairment
1. Male or female volunteers (matched to a subject with hepatic impairment in gender）；
2. Aged 18 to 70 years (matched to a subject with hepatic impairment±5 years, matched range cannot exceed±5 years)；
3. Has a body mass index of 17 to 30 kg/m2（matched to a subject with hepatic impairment±15%，matched range cannot exceed±15%）；
4. Must be in good health as determined by screening medical history, physical examination, vital signs, laboratory test, B ultrasonography and chest X ray；
5. Female volunteers must meet:
1. Has sterilization operation, or who are postmenopausal must have been postmenopausal for \>1 year, or
2. Has childbearing potential, but meet the requirement as following:
Negative pregnancy test prior to enrollment, and Agree with use 1 medical accepted methods of birth control (eg. Hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) during the whole study and continuing until 1month after the end of the study, and Non-breastfeeding；
6. Male volunteers must agree to use medical accepted method of birth control (e.g. barrier contraceptive or sexual partner use the method as (7) above) during the study and through 1month after the end of study；
7. Agree stay in ward prior to dosing within 48h, and agree not to take coffee, tea, chocolate, alcohol, grapefruit juice, orange juice and other food and drink which contain caffeine and xanthine；
8. Can sign informed consent form on his own accord；
9. Can comply with study procedures
Exclusion Criteria
* Subjects with hepatic impairment
1. Has known or suspected allergies to quinolones, fluoroquinolones, Nemonoxacin or excipients or allergic constitution；
2. Has acute disease or chronic disease which may affect PK profile of drug in vivo except the disease caused hepatic function impaired；
3. Has abnormal result of laboratory tests with clinical significance except which caused by the disease of hepatic function impaired；
4. Has history of clinically significant cardiovascular, neurological or psychiatric, gastrointestinal, pulmonary, renal, endocrine disease prior to study within 1 year；
5. Has disease seriously affect the immune system such as hematological disease, malignant tumor, or taking immunosuppressant；
6. Has acute or sub-acute hepatic function failure；
7. Has experienced esophageal variceal bleeding within the past 6 months；
8. Has advanced ascites or spontaneous bacterial peritonitis；
9. Has a history of Gilbert's disease；
10. Has resistance or liver function abnormal after orally taking nucleoside analogue, an antiviral drug；
11. Stop taking nucleoside analogue, an antiviral drug within 1 year；
12. Has total bilirubin\>3×upper limit of normal (ULN) and without cholestasis; alkaline phosphatase (ALP)\>2×ULN；
13. Alanine Aminotransferase (ALT)or Aspartate Aminotransferase（AST）\>5×ULN；
14. ALT or AST\>3×ULN with total bilirubin\>2×ULN；
15. international senstibity index，INR≥1.5 or prothrombin time activity≤40%；
16. Child-Pugh assessed as C level；
17. Has a history of alcoholism within 2 years prior to dosing; drink≥12 times within 3 months prior dosing; alcohol test positive as screening；
18. Has history of drug misuse within 2 years prior to dosing; urine drug screen positive；
19. Has history of taking products of tobacco or nicotine more than 5 cigarettes/day within 1 month prior to dosing, or cannot stop smoking during the study;
20. Use of another investigational drug or drug which can damage hepatic function within 3 months prior to dosing；
21. Use of drugs affect function of liver metabolism enzyme (e.g. benzene, isopropyl amine, the barbiturates benzodiazepines, marijuana, cocaine, opiates and phencyclidine) within 30 days prior to dosing ；
22. Has to take the drug which may affect the PK profile of investigate drug (e.g. antacids, sucralfate, metal cation, calcium supplements, warfarin, non-steroidal anti-inflammatory drugs, theophylline, cyclosporine, probenecid and cimetidine) ；
23. Has gastrointestinal disease or malabsorption syndrome affecting drug Absorb；
24. Has history of seizures or central nervous system disease which the investigator considers to interfere with compliancy of protocol; or has risk of suicide；
25. Clinical significant abnormal 12-lead electrocardiograms (ECGs) at screening (eg. atrioventricular block, torsades de pointes ventricular tachycardia (TdT), and other types of ventricular tachycardia, ventricular fibrillation, ventricular flutter, T wave change with clinical significance or any abnormal results of 12-lead ECG which affect QTc interphase) ；
26. HIV or syphilis RPR test positive；
27. Conditions investigator consider not suitable to be enrolled in the study. Healthy subjects without hepatic impairment
<!-- -->
1. Has known or suspected allergies to quinolones, fluoroquinolones, nemonoxacin or excipients or allergic constitution；
2. Has a history of alcoholism within 2 years prior to dosing; drink≥12 times within 3 months prior dosing; alcohol test positive as screening；
3. Has history of drug misuse within 2 years prior to dosing; urine drug screen positive；
4. Has history of taking products of tobacco or nicotine more than 5 cigarettes/day within 1 month prior to dosing, or cannot stop smoking during the study；
5. Donated blood or use of another investigational drug within 3 months prior to dosing；
6. Has history of chronic liver, renal, cardiovascular, neurological or psychiatric, gastrointestinal, pulmonary, urinary, endocrine disease cannot controlled by drugs；
7. Use of drugs affect function of liver metabolism enzyme within 30 days prior to dosing; or need to take medications which may affect the PK profile of investigational drug (including: products containing Calcium, aluminum, magnesium, iron and zinc, sucralfate, antacid, nutrition supplements, Vitamins and metal supplements) during the study；
8. Is taking any antibacterial agents or prophylaxis or treatment drugs；
9. HIV-Ab, HBsAg ,HCV-Ab or syphilis RPR positive；
10. Clinical significant abnormal 12-lead electrocardiograms (ECGs) at screening (eg. atrioventricular block, torsades de pointes ventricular tachycardia (TdT), and other types of ventricular tachycardia, ventricular fibrillation, ventricular flutter, T wave change with clinical significance or QTc\>450ms) ；
11. Has abnormal result of laboratory test with clinical significance assessed by investigator at screening；
12. Has gastrointestinal disease or malabsorption syndrome affecting drug Absorb；
13. Has history of seizures or central nervous system disease which the investigator considers to interfere with compliancy of protocol; or has risk of suicide；
14. Has any antibacterials, glucocorticoids, immunosuppressive agents or drug may damage organs within 14 days prior to dosing；
15. Cannot orally take drug；
16. Has history of or currently has disease and condition may affect the safety and efficancy assessment of investigational drug judged by investigator；
17. Is a member of the clinical site personnel directly affiliated with this study；
18. Conditions investigator consider not suitable to be enrolled in the study.
1. Has known or suspected allergies to quinolones, fluoroquinolones, Nemonoxacin or excipients or allergic constitution；
2. Has acute disease or chronic disease which may affect PK profile of drug in vivo except the disease caused hepatic function impaired；
3. Has abnormal result of laboratory tests with clinical significance except which caused by the disease of hepatic function impaired；
4. Has history of clinically significant cardiovascular, neurological or psychiatric, gastrointestinal, pulmonary, renal, endocrine disease prior to study within 1 year；
5. Has disease seriously affect the immune system such as hematological disease, malignant tumor, or taking immunosuppressant；
6. Has acute or sub-acute hepatic function failure；
7. Has experienced esophageal variceal bleeding within the past 6 months；
8. Has advanced ascites or spontaneous bacterial peritonitis；
9. Has a history of Gilbert's disease；
10. Has resistance or liver function abnormal after orally taking nucleoside analogue, an antiviral drug；
11. Stop taking nucleoside analogue, an antiviral drug within 1 year；
12. Has total bilirubin\>3×upper limit of normal (ULN) and without cholestasis; alkaline phosphatase (ALP)\>2×ULN；
13. Alanine Aminotransferase (ALT)or Aspartate Aminotransferase（AST）\>5×ULN；
14. ALT or AST\>3×ULN with total bilirubin\>2×ULN；
15. international senstibity index，INR≥1.5 or prothrombin time activity≤40%；
16. Child-Pugh assessed as C level；
17. Has a history of alcoholism within 2 years prior to dosing; drink≥12 times within 3 months prior dosing; alcohol test positive as screening；
18. Has history of drug misuse within 2 years prior to dosing; urine drug screen positive；
19. Has history of taking products of tobacco or nicotine more than 5 cigarettes/day within 1 month prior to dosing, or cannot stop smoking during the study;
20. Use of another investigational drug or drug which can damage hepatic function within 3 months prior to dosing；
21. Use of drugs affect function of liver metabolism enzyme (e.g. benzene, isopropyl amine, the barbiturates benzodiazepines, marijuana, cocaine, opiates and phencyclidine) within 30 days prior to dosing ；
22. Has to take the drug which may affect the PK profile of investigate drug (e.g. antacids, sucralfate, metal cation, calcium supplements, warfarin, non-steroidal anti-inflammatory drugs, theophylline, cyclosporine, probenecid and cimetidine) ；
23. Has gastrointestinal disease or malabsorption syndrome affecting drug Absorb；
24. Has history of seizures or central nervous system disease which the investigator considers to interfere with compliancy of protocol; or has risk of suicide；
25. Clinical significant abnormal 12-lead electrocardiograms (ECGs) at screening (eg. atrioventricular block, torsades de pointes ventricular tachycardia (TdT), and other types of ventricular tachycardia, ventricular fibrillation, ventricular flutter, T wave change with clinical significance or any abnormal results of 12-lead ECG which affect QTc interphase) ；
26. HIV or syphilis RPR test positive；
27. Conditions investigator consider not suitable to be enrolled in the study. Healthy subjects without hepatic impairment
<!-- -->
1. Has known or suspected allergies to quinolones, fluoroquinolones, nemonoxacin or excipients or allergic constitution；
2. Has a history of alcoholism within 2 years prior to dosing; drink≥12 times within 3 months prior dosing; alcohol test positive as screening；
3. Has history of drug misuse within 2 years prior to dosing; urine drug screen positive；
4. Has history of taking products of tobacco or nicotine more than 5 cigarettes/day within 1 month prior to dosing, or cannot stop smoking during the study；
5. Donated blood or use of another investigational drug within 3 months prior to dosing；
6. Has history of chronic liver, renal, cardiovascular, neurological or psychiatric, gastrointestinal, pulmonary, urinary, endocrine disease cannot controlled by drugs；
7. Use of drugs affect function of liver metabolism enzyme within 30 days prior to dosing; or need to take medications which may affect the PK profile of investigational drug (including: products containing Calcium, aluminum, magnesium, iron and zinc, sucralfate, antacid, nutrition supplements, Vitamins and metal supplements) during the study；
8. Is taking any antibacterial agents or prophylaxis or treatment drugs；
9. HIV-Ab, HBsAg ,HCV-Ab or syphilis RPR positive；
10. Clinical significant abnormal 12-lead electrocardiograms (ECGs) at screening (eg. atrioventricular block, torsades de pointes ventricular tachycardia (TdT), and other types of ventricular tachycardia, ventricular fibrillation, ventricular flutter, T wave change with clinical significance or QTc\>450ms) ；
11. Has abnormal result of laboratory test with clinical significance assessed by investigator at screening；
12. Has gastrointestinal disease or malabsorption syndrome affecting drug Absorb；
13. Has history of seizures or central nervous system disease which the investigator considers to interfere with compliancy of protocol; or has risk of suicide；
14. Has any antibacterials, glucocorticoids, immunosuppressive agents or drug may damage organs within 14 days prior to dosing；
15. Cannot orally take drug；
16. Has history of or currently has disease and condition may affect the safety and efficancy assessment of investigational drug judged by investigator；
17. Is a member of the clinical site personnel directly affiliated with this study；
18. Conditions investigator consider not suitable to be enrolled in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huashan Hospital
OTHER
Sponsor Role
collaborator
Zhejiang Medicine Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jing Zhang, Doctor
Role: PRINCIPAL_INVESTIGATOR
Huashan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Kang Y, Li Y, Xu F, Zhang J, Wang K, Chen Y, Wu J, Guo B, Yu J, Zhang Y. Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Clin Ther. 2019 Mar;41(3):505-517.e0. doi: 10.1016/j.clinthera.2019.01.015. Epub 2019 Feb 26.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XCNN-150830-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476
COMPLETED
PHASE1
A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
NCT05624944
COMPLETED
PHASE1
Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet
NCT01016626
COMPLETED
PHASE1
Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects
NCT01124279
COMPLETED
PHASE1
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
NCT04056468
COMPLETED
PHASE1
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
NCT01359462
COMPLETED
PHASE1
Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.
NCT06258746
ACTIVE_NOT_RECRUITING
PHASE1
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
NCT00418626
COMPLETED
PHASE1
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
NCT02474537
COMPLETED
PHASE1
Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.
NCT06569784
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT02524717
COMPLETED
PHASE1
Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
NCT07110441
COMPLETED
PHASE1
Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency
NCT06620731
COMPLETED
PHASE1
A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B
NCT01125657
COMPLETED
PHASE1
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234
COMPLETED
PHASE1
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT03902002
COMPLETED
PHASE1
Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride
NCT06176716
RECRUITING
PHASE1
Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment
NCT07033182
COMPLETED
PHASE1
Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
NCT05856513
COMPLETED
PHASE1
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
NCT05711797
COMPLETED
PHASE1
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270
COMPLETED
PHASE1
CP-690,550 Pharmacokinetics In Healthy Chinese Subjects
NCT01101919
COMPLETED
PHASE1
Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers
NCT02529800
COMPLETED
PHASE1
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
NCT05814926
COMPLETED
PHASE1
Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China
NCT00858325
COMPLETED
PHASE1